CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Athersys Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Athersys Inc
3201 Carnegie Ave
Phone: (216) 431-9900p:216 431-9900 CLEVELAND, OH  44115-2634  United States Ticker: ATHX ATHX

Filed for Bankruptcy on 1/5/2024
Case #24-10043, filed in the U.S. Bankruptcy Court for the Northern District of Ohio (Cleveland)

Business Summary
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
9995 Non-operating establishments

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Jane G.Wasman 67 10/2/2023 11/12/2020
Interim Chief Financial Officer KaseyRosado 50 8/4/2022 8/4/2022
Independent Director NeemaMayhugh 47 8/11/2023 8/11/2023
Independent Director JosephNolan 60 1/3/2023 1/3/2023
Independent Director Jack L.Wyszomierski 67 6/17/2010 6/17/2010

Subsidiaries
Business Name Address City State/Province Country
Advanced Biotherapeutics, Inc. 1625 Rockwell Avenue Cleveland OH United States

Business Names
Business Name
ABT Holding Company
Advanced Biotherapeutics, Inc.
AHYS
6 additional Business Names available in full report.

General Information
Number of Employees: 24 (As of 12/31/2022)
Outstanding Shares: 61,718,765 (As of 11/21/2023)
Shareholders: 414
Stock Exchange: OTC
Federal Tax Id: 341830213
Fax Number: (216) 361-9495


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024